Novartis Ag (NVS) Cash & Current Investments (2017 - 2025)

Novartis Ag's Cash & Current Investments history spans 9 years, with the latest figure at $11.7 billion for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 161.07% year-over-year to $11.7 billion; the TTM value through Dec 2025 reached $11.7 billion, up 161.07%, while the annual FY2025 figure was $11.7 billion, 161.07% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $11.7 billion at Novartis Ag, up from $4.5 billion in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $28.3 billion in Q4 2021 and bottomed at $4.5 billion in Q4 2024.
  • The 5-year median for Cash & Current Investments is $14.0 billion (2023), against an average of $15.4 billion.
  • The largest annual shift saw Cash & Current Investments plummeted 67.93% in 2024 before it surged 161.07% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $28.3 billion in 2021, then plummeted by 34.32% to $18.6 billion in 2022, then decreased by 24.96% to $14.0 billion in 2023, then tumbled by 67.93% to $4.5 billion in 2024, then soared by 161.07% to $11.7 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Cash & Current Investments are $11.7 billion (Q4 2025), $4.5 billion (Q4 2024), and $14.0 billion (Q4 2023).